Report copyright - Updated Efficacy and Safety From the Phase 3 RESONATE-2 ™ Study: Ibrutinib as First ... · 2017. 2. 7. · ASH 2016, Updated Efficacy/Safety RESONATE-2; Barr et al. CLL: older population
Please pass captcha verification before submit form